Peptides for Immunotherapy & Vaccines

At JPT Peptide Technologies, we specialize in cutting-edge peptide-based solutions for immunotherapy and vaccine development. Our advanced technologies enable comprehensive B- and T-cell biomarker discovery, immune monitoring, and facilitate the clinical development of therapies aimed at treating a variety of diseases. From cancer to autoimmune disorders and infectious diseases, our peptides are paving the way for more targeted, effective immunotherapies and vaccines.

Our Unique Peptide-Based Technologies

JPT Peptide Technologies leverages a diverse range of proprietary technologies for peptide synthesis and design, allowing us to address specific immunotherapy needs. These include:

  • Systematic B- and T-cell biomarker discovery: Our peptide libraries span the entire proteome, enabling the identification of critical biomarkers for effective immune monitoring.
  • Epitope mapping and monitoring: We offer tools to monitor individual epitope patterns, which are critical for understanding immune response. Our approach also includes tracking epitope spreading, which provides insights into how immune responses evolve during therapy.
  • Natural sequence diversity & post-translational modifications: Unlike other market approaches, ou r technologies account for natural sequence variation and post-translational modifications, providing a more accurate and personalized immune profile.

peptide tools für cell therapy

Applications of Peptide Technologies in Immunotherapy and Vaccines

Our peptide technologies have been applied across numerous therapeutic areas:

1. Cancer Immunotherapy

Our peptide-based solutions aid in the development of personalized cancer vaccines by identifying tumor-specific antigens. This allows for a targeted immune response, improving therapeutic outcomes in cancers like melanoma, breast cancer, and prostate cancer.

2. Infectious Diseases

In combating viral and bacterial infections, peptides offer a way to enhance vaccine efficacy by focusing on immune system training. Our solutions have been involved in projects targeting HIV, influenza, and COVID-19, contributing to the development of more effective vaccines.

3. Autoimmune Diseases & Allergy

In autoimmune diseases such as multiple sclerosis or rheumatoid arthritis, peptide-based immunotherapies can modulate immune activity to prevent it from attacking the body’s own tissues. We also provide solutions for monitoring allergen-specific immune responses, aiding in the development of vaccines for allergies.

Why Choose JPT Peptide Technologies for Immunotherapy & Vaccine Development?

  • Comprehensive Immune Monitoring: Our tools provide a broad and detailed understanding of immune responses, crucial for the development of effective immunotherapies.
  • Epitope Focus: Monitoring epitope patterns and addressing epitope spreading during treatment is unique to our approach and essential for understanding long-term immune response.
  • Customization: We tailor our peptide solutions to meet the specific needs of your project, whether you're targeting infectious diseases, cancer, or autoimmune conditions.

Contact Us for Further Information

Our team at JPT Peptide Technologies is dedicated to advancing the science of immunotherapy and vaccine development. Whether you are working on a clinical trial, biomarker discovery, or immune monitoring project, we are here to provide the peptide tools and expertise you need. Contact us today for more information on how we can collaborate to accelerate your research and development efforts.


Applications

Applications

  • Epitope discovery: JPT offers its technologies and expertise in discovery projects targeting specific B- and T-cell epitopes that can be used as markers for early diagnosis and progression of diseases as well as patient stratification. For the first time, high-throughput proteome spanning screening can be combined with high resolution epitope based profiling.
  • Development of immune monitoring tools: JPT applies its patented approaches and know-how to develop peptide based immune monitoring tools targeting specific antigens or antigen families. The combination of technological and bioinformatic know-how with profound expertise in assay development provides efficient access to epitope resolved profiling for cellular and humoral immune responses.
  • Assay development & sample profiling: JPT’s experienced scientists will work with you to develop the optimal screening strategy for your project. Seroprofiling assays and T cell assays are performed in JPT’s S2 laboratories using automatic incubation stations and trained staff assuring performance of robust and reproducible results.

Benefits

Benefits

  • Broad peptide technology portfolio for all development phases of immunotherapies and vaccines 
  • Peptide platforms covering cellular and humoral immunity
  • Ultra-high content peptide library concepts for deep epitope and target discovery 
  • Clinical peptides
  • Chemical synthesis addresses sequence diversity and post-translational modifications 
  • State of the art infrastructure allowing organic chemistry, sensitive production workflows (cleanroom) and assays including usage of infectious patient materials (S2 and gene tech laboratories)
  • Comprehensive bioinformatics for peptide selection and design

References

References

  • A Vaccine Based on Recombinant Modified Vaccinia Ankara Containing the Nucleoprotein from Lassa Virus Protects Against Disease Progression in a Guinea Pig Model
    Kennedy et al, Vaccine (2019) 
  • Original Antigenic Sin Shapes the Immunological Repertoire Evoked by Human Cytomegalovirus Glycoprotein B/MF59 Vaccine in Seropositive Recipients
    Baraniak et al, Journal of Infectious Disease (2019)
  • Mass Spectrometry Driven Exploration Reveals Nuances of Neoepitope-Driven Tumor Rejection
    Ebrahimi-Nik et al, JCI Insight (2019)
  • New Epitopes in Ovalbuminprovide Insights For Cancer Neoepitopes
    Karandikar et al, Immunology (2019) 
  • Therapy-Induced MHC I Ligands Shape Neo-Antitumor CD8 T Cell Responses during Oncolytic Virus-Based Cancer Immunotherapy
    Murphy et al, Journal of Proteome Research (2019)
  • Natural T Cell Autoreactivity to Melanoma Antigens: Clonally Expanded Melanoma-Antigen Specific CD8 + Memory T Cells Can be Detected in Healthy Humans
    Przybyla et al, Cancer Immunology, Immunotherapy (2019) 
  • Characterization of the Immune Response Elicited by the Vaccinia Virus L3 Protein Delivered as Naked DNA
    Ramírez et al, Vaccine (2018) 
  • Epstein-Barr Virus (EBV)-derived BARF1 Encodes CD4-and CD8-restricted Epitopes as Targets for T-cell Immunotherapy
    Kalra et al, Cytotherapy (2018)
  • PRAME Peptide‐Specific CD8+ T Cells Represent the Predominant Response Against Leukemia‐Associated Antigens (LAAs) in Healthy Individuals
    Matko et al, European Journal of Immunology (2018) 
  • Coordinated Responses to Individual Tumor Antigens by IgG Antibody and CD8+ T cells Following Cancer Vaccination
    Hulett et al, Journal for ImmunoTherapy of Cancer (2018)

Loading...

Check our list of products, click and go.

Get a quote